The concept of 'idiopathic'Parkinson's disease (PD) as a single entity has been challenged
with the identification of several clinical subtypes, pathogenic genes and putative causative …

Parkinson's disease (PD) is a highly heterogeneous disorder, which probably consists of
multiple subtypes. Aggregation of misfolded alpha-synuclein and propagation of these …

Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

In the past few months, the world seems to have come to a virtual standstill. As the SARS-
CoV-2 virus continues to spread across the globe, many countries have taken drastic …

Parkinson's disease (PD) starts at the molecular and cellular level long before motor
symptoms appear, yet there are no early-stage molecular biomarkers for diagnosis …

The Parkinson's disease (PD) research field has seen the advent of several promising
biomarkers and a deeper understanding of the clinical features of the disease from the …

Gene set enrichment analysis has become one of the most frequently used applications in
molecular biology research. Originally developed for gene sets, the same statistical …

Background: We aimed to predict Montreal Cognitive Assessment (MoCA) scores in
Parkinson's disease patients at year 4 using handcrafted radiomics (RF), deep (DF), and …

The ability to use blood to predict the outcomes of Parkinson's disease, including disease
progression and cognitive and motor complications, would be of significant clinical value …

Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …